Feeds:
Posts
Comments

Posts Tagged ‘revlimid’

Welcome back from Thanksgiving holiday! Can’t believe it’s already December…

This will be the only Impactiviti Daily this week, as I am heading down to South Carolina for the graduation of my #2 son (David) from Marine boot camp.

TODAY’S NEWS

Layoffs. Sanofi reps are apparently getting the news this week. Ugh.

Will Celgene‘s Revlimid take off even faster? – Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Johnson & Johnson’s intravenous medicine, Velcade.

Court to Glaxo reps seeking overtime pay: No. FDA to Novartis on seasonal flu shot: Yes.

RECOMMENDED

Speaker Training. The Impactiviti network of providers has what you need.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Mystic the Marketing Lab gives her first interview. On canine branding.

JUST FOR FUN

Twenty amazing photographers from around the Internet.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Some interesting oncology results:

Millennium‘s Velcade used in combo therapy for multiple myeloma shows impressive results.

Cephalon‘s Treanda shows impressive remission numbers for CLL, and effectiveness in non-Hodgins lymphoma (NHL).

Celgene‘s Revlimid continues to produce good results at a low-dose regimen.

Novartis‘ Gleevec: effective at halting leukemia progression up to 6 years.

Eisai decides to grab MGI Pharma, and its stable of oncology drugs.

Biogen-Idec‘s Zevalin, a radioimmunotherapy agent, halted NHL progression in 76% of patients (single treatment!).

AZ’s Arimidex shown superior to tamoxifen for breast cancer, even 4 years after treatment.

GSK‘s Tykerb helps fight brain tumors in combo with Xeloda.

And, on the bleeding edge:

Prasugrel (new blood thinning treatment from Daiichi-Sankyo and Lilly) continues to show promise – and some mixed results in certain populations.

Glaxo‘s experimental platelet booster shows efficacy in long-term treatment (Glaxo also announced new deals with 2 biotechs). However, GSK is now hit with a delay on its Cervarix vaccine.

Bayer and J&J’s experimental blood thinner takes on market-leader Lovenox in blood clot prevention study.

WSJ has summary article on the blood thinner race to market.

And, in other news:

Novartis the latest to announce major job cuts.

Merck still developing obesity and cholesterol drugs.

FDA approves new blood pressure drug from Mylan/Forest.

Lilly CEO to retire.

Changing endpoints…a clinical study no-no. WSJ has the story, on a long-delayed Vytorin study.

Is Alzheimer’s a form of diabetes? Very intriguing line of research…

Read Full Post »

Glaxo buying Reliant – GlaxoSmithKline Plc has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, in a move to boost its flagging drug sales in the United States…more

J&J says good-bye to $440 mil – Johnson & Johnson said on Thursday its fourth-quarter results would include a special after-tax, noncash charge of $440 million from a write-down related to a decline in sales of acute heart failure drug Natrecor…more

Fountain of youth? – Scientists at Sirtris Pharmaceuticals Inc. say they have created a drug that mimics the ingredient in red wine linked to longevity and the cell structures that power endurance athletes like cycling champion Lance Armstrong. The new molecule is 1,000 times more potent than the wine derivative, resveratrol, and could lead to solutions for diseases of aging, including cancer and diabetes, according to authors of a study in today’s issue of the journal Nature…more

Abbott‘s Xience stent showing good side effect profile and efficacy…gets FDA panel green light – Abbott Laboratories Inc  won a U.S. advisory panel’s support on Thursday for an experimental drug-coated stent for heart patients. A committee of advisers to the Food and Drug Administration voted 9-1 to recommend approval of the device, called Xience. The FDA usually follows panel recommendations…more

On the Oncology front…

Novartis gets EU approval for Tasigna – Novartis AG (NVS) Wednesday said that Tasigna, a potential follow-up to Gleevec, the Swiss drugmaker’s second best-selling drug, won European Union approval for the treatment of a certain form of leukemia. Novartis, based in Basel, said Tasigna is a new targeted cancer drug for patients with a form of the life-threatening blood cancer chronic myeloid leukemia, who are resistant or intolerant to treatment with Gleevec. Novartis expects Tasigna to eventually replace Gleevec and plans to test its efficacy and safety in patients who haven’t yet been treated with Gleevec…more

Celgene‘s Revlimid combined with dexamethasone effective for multiple myeloma – A combination drug regimen that includes a derivative of thalidomide extended survival, as well as the time it took for the disease to reappear, in patients with multiple myeloma…more

Freeze tumors, reduce pain – Freezing tumors may help relieve the extreme pain of cancer that has spread to the bone, which is often untouched by narcotics or radiation, U.S. researchers said on Tuesday. This freezing process, called cryoablation, is often used to destroy kidney, prostate and other tumors, but researchers at the Mayo Clinic in Rochester, Minnesota, found it eased cancer pain in 80 percent of patients in a small study, and the effect lasted for up to six months…more

It’s not drugs, but it’s fascinating – Vivek Rangnekar, a University of Kentucky College of Medicine professor of radiation medicine and a team of researchers say they have found a tumor-suppressor gene called “Par-4” in the prostate. The researchers discovered that the Par-4 gene kills cancer cells, even highly aggressive types, but not normal cells, according to a study published in the journal Cancer Research and funded by grants from the National Institutes of Health. Rangnekar’s study found that mice born with this gene do not develop tumors. They grow normally, have no defects and actually live a few months longer than the control animals…more

Read Full Post »